A Jazz Pianist's Metoprolol and the Question He Almost Didn't Ask
He almost didn't bring it up. Once he did, the actual pharmacology turned out to matter: not every beta-blocker affects this the same way.
M.S., a 61-year-old man, has played piano professionally in jazz clubs for almost forty years and still books three or four nights a week, later hours than most people his age keep by choice. He was diagnosed with hypertension two years ago and started on metoprolol tartrate, uptitrated in steps since and reaching his current 100 mg twice daily about four months ago, alongside a low-sodium diet he says he mostly follows on tour and rarely follows at home. He has no coronary disease, no diabetes, and no prior cardiac events; the hypertension itself was picked up incidentally at a routine physical rather than through any symptom. He mentioned, almost as an aside at the end of today's visit, that he's had new difficulty with erections over the past several months — something he said he'd been reluctant to bring up and only did because his wife encouraged him to.
The timing lines up with his metoprolol titration, and beta-blockers as a class are a well-documented, dose-dependent cause of erectile dysfunction, thought to work partly by blunting the sympathetic-nervous-system component of arousal and partly through effects on penile blood flow. What complicates a simple stop-the-beta-blocker response is that not every agent in the class behaves the same way pharmacologically: nebivolol is a beta-1-selective blocker with an additional, distinct mechanism — it stimulates nitric oxide (NO) release and produces genuine vasodilation, the opposite physiologic direction from the vasoconstrictive tendency of older agents like metoprolol and atenolol. Comparative studies have found nebivolol associated with substantially less sexual dysfunction than traditional beta-blockers, and in some analyses no worse than placebo, making a within-class switch a real option rather than only a between-class one.
At the follow-up visit
The timing and the mechanism both point to metoprolol. Beta-blockers are a well-established, dose-dependent cause of erectile dysfunction, and his symptoms tracking his titration isn't a coincidence I'd want to explain away. I'd want to change something, not just reassure him it's unrelated.
I'd push toward a within-class switch before reaching for an entirely different drug class. Nebivolol works differently from metoprolol in a way that's directly relevant here — it stimulates nitric oxide release and causes vasodilation rather than the vasoconstrictive tendency older beta-blockers share, and comparative studies have found it associated with meaningfully less sexual dysfunction than traditional agents.
That's a cleaner solution than switching classes entirely, since it keeps him on a drug with a strong track record for his blood pressure control without introducing a new mechanism I'd have to titrate from scratch. Switching to nebivolol, same beta-1-selective target — starting at its usual 5 mg once-daily initial dose, which is a starting point rather than a milligram equivalent of the 200 mg of metoprolol he comes off, so he needs home readings and retitration rather than an assumption that control carries over.
Metoprolol tartrate discontinued; nebivolol started at 5 mg daily with a plan to retitrate against home blood pressure readings over the following month.
Agreed without real disagreement on the switch itself; the standing note left for follow-up:
If erectile dysfunction persists despite the switch to nebivolol, the working assumption that metoprolol was the specific cause would need to be reconsidered rather than simply tried against a third agent by default.